user avatar
VKPrasadLab
@vkprasadlab
These posts were issued before my FDA employment and do not necessarily represent the views of the FDA or the United States. The account is now inactive.
Joined April 2021
Posts
  • Pinned
    user avatar
    Here is a running thread of the articles we have published in 2023 with links to tweetorials when possible But first a summary of the last 2 years, and links to all papers vkprasadlab.com/publications
  • user avatar
    Pausing NIH study sections is not a big deal NIH desperately needs reform
    00:00
  • user avatar
    Here are the peer reviewed papers we worked on in 2021 👇👇 Lots of terrific collaborations with smart people
  • user avatar
    Now out in Dig Health; We analyze Facebook's fact checking. During the pandemic, they relied heavily on high volume twitter users. In one case, user had already tweeted negatively about a paper before being selected to 'fact check' it. Seems problematic journals.sagepub.com/doi/pdf/10.117…
  • user avatar
    Red dye #3, RCTs for boosters, and what would actually give American's health
    00:00
  • user avatar
    The following is a list of all the articles we have published in 2021 1. This paper provides an overview of the indications, mechanism of action, and side effects of targeted cancer therapies.
  • user avatar
    The following is a list of all the articles we have published in 2022 1.
    Our first @vkprasadlab article of 2022 Led by UCLA Chief Jack Sharp, we show 57% of time FDA allows studies that DO NOT USE USA staging This means there may be errors in staging or occult disease that needs treatment Which may bias results 2 win 🧵 rdcu.be/cE8nL
  • user avatar
    At long last; This project took years to complete, and required a dream team of authors, but, at last, here you have it.... Reversals in hematology oncology over the last decade Open access! Credit to Alyson Haslam, the mastermind of this👇 rdcu.be/crQpQ
  • user avatar
    Just out in the British Journal of Haemaotology Ida-cel costs 420,000 per dose and cures no one Is this sustainable? reasonable? prudent? drug development By Logan Powell, @dgermain21 and @VPrasadMDMPH Free link: onlinelibrary.wiley.com/doi/epdf/10.11…
  • user avatar
    Just OUT ahead-of-print, John Ioannidis & I discuss Constructive and Obsessive Critics in Science I think we all see the latter on Twitter They focus on individuals & not ideas 👇👇 Often Lack technical expertise & make scientific debates -> moral ones 🧵 onlinelibrary.wiley.com/doi/abs/10.111…
  • user avatar
    This week in @JAMAInternalMed we explore the relationship between drug price and anti-cancer drug benefit (2015-20), led by @miljko & jordan tuia @vkprasadlab We have been working in this space for 10 years now First, some background 🧵🧵 jamanetwork.com/journals/jamai…
  • user avatar
    Medical Student and VKPrasadLab member, Logan Powell, is participating in an IRONMAN triathlon to raise money for charity – donations can be made at the link below! ironmanfoundation.donordrive.com/index.cfm?fuse…
  • user avatar
    Our new paper OUT TODAY We calculate the cost to avert a SINGLE DFS event of all the new "game-changer" Cancer drugs Median is 1.6 MILLION USD, up to 2.6 MIL!! These costs will BANKRUPT us Based on power calcs, this is the trial GOAL! No surprise Sad! jamanetwork.com/journals/jaman…
  • user avatar